Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Enterprise Value (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Enterprise Value for 16 consecutive years, with -$81.2 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 2.46% to -$81.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$81.2 million through Dec 2025, down 2.46% year-over-year, with the annual reading at -$81.2 million for FY2025, 2.46% down from the prior year.
  • Enterprise Value for Q4 2025 was -$81.2 million at Anika Therapeutics, down from -$80.2 million in the prior quarter.
  • The five-year high for Enterprise Value was -$75.4 million in Q1 2025, with the low at -$124.2 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$99.3 million, with a median of -$96.9 million recorded in 2021.
  • The sharpest move saw Enterprise Value surged 32.69% in 2021, then plummeted 34.04% in 2022.
  • Over 5 years, Enterprise Value stood at -$124.2 million in 2021, then rose by 2.64% to -$121.0 million in 2022, then grew by 21.38% to -$95.1 million in 2023, then increased by 16.7% to -$79.2 million in 2024, then dropped by 2.46% to -$81.2 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$81.2 million, -$80.2 million, and -$77.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.